TriSalus Life Net Income Over Time
| TLSI Stock | 4.95 0.27 5.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out TriSalus Life Performance and TriSalus Life Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will TriSalus introduce new products? Factors like these will boost the valuation of TriSalus Life. If investors know TriSalus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about TriSalus Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth 0.574 | Return On Assets | Return On Equity |
Investors evaluate TriSalus Life Sciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating TriSalus Life's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause TriSalus Life's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between TriSalus Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if TriSalus Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, TriSalus Life's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare TriSalus Life Sciences and related stocks such as Profound Medical Corp, MaxCyte, and Perspective Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PROF | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (11.8 M) | (12.1 M) | (15 M) | (15.2 M) | (15.2 M) | (21.6 M) | (30.7 M) | (28.7 M) | (28.6 M) | (26.5 M) | (23.8 M) | (25 M) |
| MXCT | (2 M) | (2 M) | (2 M) | (958.2 K) | (1.8 M) | (1.4 M) | (3.3 M) | (9.9 M) | (8.9 M) | (12.9 M) | (11.8 M) | (19.1 M) | (23.6 M) | (37.9 M) | (41.1 M) | (36.9 M) | (35.1 M) |
| CATX | (437.6 K) | (2.8 M) | (3.5 M) | (3.9 M) | (6 M) | (3.7 M) | (4.7 M) | (6.2 M) | (4.8 M) | (3.3 M) | (3.2 M) | (7.3 M) | (14.7 M) | (46.5 M) | (79.3 M) | (71.4 M) | (67.8 M) |
| AVR | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (17.2 M) | (30.6 M) | (46 M) | (76.3 M) | (68.7 M) | (65.2 M) |
| PRE | 142.3 M | 1.1 B | 1.1 B | 664 M | 1.1 B | 104.4 M | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (1.9 M) | (174 M) | (190.5 M) | (62.7 M) | (46.3 M) | (41.7 M) | (39.6 M) |
| LNSR | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (14.7 M) | (19.8 M) | (19.6 M) | (19.9 M) | (14.4 M) | (31.4 M) | (28.3 M) | (29.7 M) |
| NNOX | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (22.6 M) | (43.5 M) | (61.8 M) | (105.2 M) | (60.8 M) | (53.5 M) | (48.2 M) | (50.6 M) |
| OWLT | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (10.5 M) | (71.7 M) | (79.3 M) | (32.9 M) | (12.5 M) | (11.3 M) | (11.8 M) |
| STIM | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (16.1 M) | (24.1 M) | (29 M) | (27.5 M) | (31.2 M) | (37.2 M) | (30.2 M) | (43.7 M) | (39.3 M) | (41.3 M) |
| ARMP | (5.1 M) | (3.8 M) | (1.1 M) | (64.6 M) | 23.1 M | (516 K) | (18.8 M) | (12.8 M) | (12.1 M) | (19.5 M) | (22.2 M) | (23.2 M) | (36.9 M) | (69 M) | (18.9 M) | (17 M) | (17.9 M) |
TriSalus Life Sciences and related stocks such as Profound Medical Corp, MaxCyte, and Perspective Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in TriSalus Life Sciences financial statement analysis. It represents the amount of money remaining after all of TriSalus Life Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| TriSalus Life Sciences | TLSI |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 6272 West 91st |
| Exchange | NASDAQ Exchange |
null 4.95
Check out TriSalus Life Performance and TriSalus Life Correlation. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
TriSalus Life technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.